trending Market Intelligence /marketintelligence/en/news-insights/trending/sKGJ3SVu1JPen2AxJFVXJA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Illumina's $1.2B Pacific Biosciences merger waiting period extended by FTC

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Illumina's $1.2B Pacific Biosciences merger waiting period extended by FTC

The waiting period to complete Illumina Inc.'s $1.2-billion acquisition of Pacific Biosciences of California Inc. will be extended after the U.S. Federal Trade Commission requested additional information from the companies.

San Diego-based Illumina and gene sequencing company Pacific Biosciences said the waiting period for the completion of the merger will begin after being in compliance with FTC's request.

In November 2018, Illumina said it will acquire Menlo Park, Calif.-based Pacific Biosciences for $8 per share in an all-cash transaction.

The companies still expect the merger will be completed by midyear.